APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human cytomegalovirus 65 kDa Phosphoprotein

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human cytomegalovirus 65 kDa Phosphoprotein Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025186 pages

Choose your research edition.

Industry ResearchHuman cytomegalovirus 65 kDa Phosphoprotein Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Human cytomegalovirus 65 kDa Phosphoprotein Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Human cytomegalovirus 65 kDa Phosphoprotein market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein include Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc and Vical Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human cytomegalovirus 65 kDa Phosphoprotein market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human cytomegalovirus 65 kDa Phosphoprotein and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human cytomegalovirus 65 kDa Phosphoprotein sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human cytomegalovirus 65 kDa Phosphoprotein market size, projected growth trends, production technologies, key applications, and end-use industries.

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Company

Astellas Pharma Inc

Hookipa Biotech AG

Immunomic Therapeutics Inc

Vakzine Projekt Management GmbH

Vaximm AG

VBI Vaccines Inc

Vical Inc

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Type

HB-101

ASP-0113

PepVax

CyMVectin

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Application

Hemotaological Tumor

Kidney Transplant Rejection

Brain Tumor

Liver Transplant Rejection

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human cytomegalovirus 65 kDa Phosphoprotein market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human cytomegalovirus 65 kDa Phosphoprotein and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human cytomegalovirus 65 kDa Phosphoprotein.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human cytomegalovirus 65 kDa Phosphoprotein market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human cytomegalovirus 65 kDa Phosphoprotein manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human cytomegalovirus 65 kDa Phosphoprotein in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human cytomegalovirus 65 kDa Phosphoprotein in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends Table 2. Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers Table 3. Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges Table 4. Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints Table 5. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Manufacturers Table 9. Global Human cytomegalovirus 65 kDa Phosphoprotein Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Human cytomegalovirus 65 kDa Phosphoprotein Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human cytomegalovirus 65 kDa Phosphoprotein Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers, Product Type & Application Table 13. Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human cytomegalovirus 65 kDa Phosphoprotein by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of HB-101 Table 17. Major Manufacturers of ASP-0113 Table 18. Major Manufacturers of PepVax Table 19. Major Manufacturers of CyMVectin Table 20. Major Manufacturers of Others Table 21. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 23. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 24. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2021-2026) Table 25. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2027-2032) Table 26. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2026) & (K Units) Table 28. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2027-2032) & (K Units) Table 29. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2021-2026) Table 30. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hemotaological Tumor Table 32. Major Manufacturers of Kidney Transplant Rejection Table 33. Major Manufacturers of Brain Tumor Table 34. Major Manufacturers of Liver Transplant Rejection Table 35. Major Manufacturers of Others Table 36. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 38. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 39. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2021-2026) Table 40. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2027-2032) Table 41. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2026) & (K Units) Table 43. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2027-2032) & (K Units) Table 44. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2021-2026) Table 45. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2027-2032) Table 46. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2026) & (K Units) Table 48. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2021-2026) Table 49. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 53. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 54. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 56. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 63. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2021-2026) Table 67. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2027-2032) Table 68. Astellas Pharma Inc Company Information Table 69. Astellas Pharma Inc Business Overview Table 70. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 72. Astellas Pharma Inc Recent Development Table 73. Hookipa Biotech AG Company Information Table 74. Hookipa Biotech AG Business Overview Table 75. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 77. Hookipa Biotech AG Recent Development Table 78. Immunomic Therapeutics Inc Company Information Table 79. Immunomic Therapeutics Inc Business Overview Table 80. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 82. Immunomic Therapeutics Inc Recent Development Table 83. Vakzine Projekt Management GmbH Company Information Table 84. Vakzine Projekt Management GmbH Business Overview Table 85. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 87. Vakzine Projekt Management GmbH Recent Development Table 88. Vaximm AG Company Information Table 89. Vaximm AG Business Overview Table 90. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 92. Vaximm AG Recent Development Table 93. VBI Vaccines Inc Company Information Table 94. VBI Vaccines Inc Business Overview Table 95. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 97. VBI Vaccines Inc Recent Development Table 98. Vical Inc Company Information Table 99. Vical Inc Business Overview Table 100. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 102. Vical Inc Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Human cytomegalovirus 65 kDa Phosphoprotein Distributors List Table 106. Human cytomegalovirus 65 kDa Phosphoprotein Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Human cytomegalovirus 65 kDa Phosphoprotein Product Image Figure 2. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size (2021-2032) & (US$ Million) Figure 4. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (2021-2032) & (K Units) Figure 5. Global Human cytomegalovirus 65 kDa Phosphoprotein Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human cytomegalovirus 65 kDa Phosphoprotein Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. HB-101 Image Figure 9. ASP-0113 Image Figure 10. PepVax Image Figure 11. CyMVectin Image Figure 12. Others Image Figure 13. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2021-2032) Figure 16. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2021-2032) Figure 19. Hemotaological Tumor Image Figure 20. Kidney Transplant Rejection Image Figure 21. Brain Tumor Image Figure 22. Liver Transplant Rejection Image Figure 23. Others Image Figure 24. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2021-2032) Figure 27. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2021-2032) Figure 30. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2032) Figure 32. U.S. Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2032) Figure 37. Germany Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2032) Figure 44. China Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2032) Figure 52. Brazil Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Human cytomegalovirus 65 kDa Phosphoprotein Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Figure 63. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Figure 65. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • HB-101
  • ASP-0113
  • PepVax
  • CyMVectin
  • Others
Applications
  • Hemotaological Tumor
  • Kidney Transplant Rejection
  • Brain Tumor
  • Liver Transplant Rejection
  • Others
Companies covered
  • Astellas Pharma Inc
  • Hookipa Biotech AG
  • Immunomic Therapeutics Inc
  • Vakzine Projekt Management GmbH
  • Vaximm AG
  • VBI Vaccines Inc
  • Vical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Dynamics
  1. 2.1 Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends
  2. 2.2 Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers
  3. 2.3 Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges
  4. 2.4 Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints
3 Human cytomegalovirus 65 kDa Phosphoprotein Market by Manufacturers
  1. 3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers, Product Type & Application
  7. 3.7 Global Human cytomegalovirus 65 kDa Phosphoprotein Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human cytomegalovirus 65 kDa Phosphoprotein Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human cytomegalovirus 65 kDa Phosphoprotein Tier 1, Tier 2, and Tier 3
4 Human cytomegalovirus 65 kDa Phosphoprotein Market by Type
  1. 4.1 Human cytomegalovirus 65 kDa Phosphoprotein Type Introduction
  2. 4.1.1 HB-101
  3. 4.1.2 ASP-0113
  4. 4.1.3 PepVax
  5. 4.1.4 CyMVectin
  6. 4.1.5 Others
  7. 4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type
  8. 4.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032)
  10. 4.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2021-2032)
  11. 4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type
  12. 4.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032)
  14. 4.3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2021-2032)
5 Human cytomegalovirus 65 kDa Phosphoprotein Market by Application
  1. 5.1 Human cytomegalovirus 65 kDa Phosphoprotein Application Introduction
  2. 5.1.1 Hemotaological Tumor
  3. 5.1.2 Kidney Transplant Rejection
  4. 5.1.3 Brain Tumor
  5. 5.1.4 Liver Transplant Rejection
  6. 5.1.5 Others
  7. 5.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application
  8. 5.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032)
  10. 5.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2021-2032)
  11. 5.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application
  12. 5.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032)
  14. 5.3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2021-2032)
6 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region
  1. 6.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2032)
  3. 6.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2026)
  4. 6.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region
  1. 7.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region
  2. 7.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2021-2026)
  4. 7.1.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2027-2032)
  5. 7.1.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032)
  8. 7.2.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032)
  11. 7.3.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma Inc
  2. 8.1.1 Astellas Pharma Inc Company Information
  3. 8.1.2 Astellas Pharma Inc Business Overview
  4. 8.1.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  6. 8.1.5 Astellas Pharma Inc Recent Developments
  7. 8.2 Hookipa Biotech AG
  8. 8.2.1 Hookipa Biotech AG Company Information
  9. 8.2.2 Hookipa Biotech AG Business Overview
  10. 8.2.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  12. 8.2.5 Hookipa Biotech AG Recent Developments
  13. 8.3 Immunomic Therapeutics Inc
  14. 8.3.1 Immunomic Therapeutics Inc Company Information
  15. 8.3.2 Immunomic Therapeutics Inc Business Overview
  16. 8.3.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  18. 8.3.5 Immunomic Therapeutics Inc Recent Developments
  19. 8.4 Vakzine Projekt Management GmbH
  20. 8.4.1 Vakzine Projekt Management GmbH Company Information
  21. 8.4.2 Vakzine Projekt Management GmbH Business Overview
  22. 8.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  24. 8.4.5 Vakzine Projekt Management GmbH Recent Developments
  25. 8.5 Vaximm AG
  26. 8.5.1 Vaximm AG Company Information
  27. 8.5.2 Vaximm AG Business Overview
  28. 8.5.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  30. 8.5.5 Vaximm AG Recent Developments
  31. 8.6 VBI Vaccines Inc
  32. 8.6.1 VBI Vaccines Inc Company Information
  33. 8.6.2 VBI Vaccines Inc Business Overview
  34. 8.6.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  36. 8.6.5 VBI Vaccines Inc Recent Developments
  37. 8.7 Vical Inc
  38. 8.7.1 Vical Inc Company Information
  39. 8.7.2 Vical Inc Business Overview
  40. 8.7.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  42. 8.7.5 Vical Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Analysis
  2. 9.1.1 Human cytomegalovirus 65 kDa Phosphoprotein Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process
  6. 9.2 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors
  9. 9.2.3 Human cytomegalovirus 65 kDa Phosphoprotein Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst